Group | N | Pre-Intervention | Post-Intervention | Δ (%) | |
---|---|---|---|---|---|
IGF-1 (ng/mL) | EXP | 24 | 119.0 (57.6) | 139.2 (85.4) | + 17.0 |
-hrMCI | 12 | 118.0 (55.2) | 143.2 (81.2) | + 21.4 | |
-lrMCI | 12 | 120.1 (62.4) | 135.3 (92.8) | + 12.7 | |
CON | 18 | 112.5 (50.2) | 136.3 (66.4) | + 21.2 | |
-hrMCI | 8 | 117.7 (58.3) | 141.3 (58.3) | + 20.1 | |
-lrMCI | 10 | 108.3 (45.5) | 132.4 (75.1) | + 22.2 | |
Total | 42 | 116.2 (54.0) | 138.0 (77.0) | + 18.8 | |
-hrMCI | 20 | 117.9 (54.9) | 142.4 (71.2) | + 20.8 | |
-lrMCI | 22 | 114.7 (54.4) | 133.9 (83.3) | + 16.7 | |
IL-6 (pg/mL) | EXP | 23 | 8.5 (9.2) | 12.2 (12.2) | + 43.5 |
-hrMCI | 12 | 6.7 (5.5) | 10.3 (11.2) | + 53.7 | |
-lrMCI | 11 | 10.5 (12.0) | 14.4 (13.5) | + 37.1 | |
CON | 20 | 7.7 (8.2) | 7.2 (8.9) | -6.5 | |
-hrMCI | 10 | 4.5 (4.2) | 4.1 (3.1) | -8.9 | |
-lrMCI | 10 | 11.2 (10.2) | 10.7 (11.8) | -4.5 | |
Total | 43 | 8.1 (8.6) | 9.9 (11.0) | + 22.2 | |
-hrMCI | 22 | 5.6 (4.9) | 7.3 (8.8) | + 30.4 | |
-lrMCI | 21 | 10.8 (10.9) | 12.7 (12.6) | + 17.6 | |
KYN (ng/mL) | EXP | 23 | 1582.3 (755.7) | 1301.3 (606.4) | -17.8 |
-hrMCI | 11 | 1434.8 (650.6) | 1442.3 (579.5) | + 0.5 | |
-lrMCI | 12 | 1717.4 (846.1) | 1172.2 (626.2) | + 46.5 | |
CON | 22 | 1616.4 (709.1) | 1507.1 (578.2 | -6.8 | |
-hrMCI | 12 | 1308.2 (441.0) | 1722.2 (593.8) | + 31.6 | |
-lrMCI | 10 | 2017.2 (808.8) | 1227.5 (439.8) | -39.1 | |
Total | 45 | 1599.3 (724.8) | 1404.2 (595.0) | -12.2 | |
-hrMCI | 23 | 1366.2 (538.2) | 1593.9 (591.8) | + 16.7 | |
-lrMCI | 22 | 1853.7 (823.8) | 1197.3 (537.7) | -35.4 |